Clinical Trial Update: Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Bintrafusp alfa in combination with stereotactic body radiation therapy for recurrent or second primary head and neck squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Bintrafusp alfa (bintrafusp alfa)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-23